Company intelligence / Profile preview

Edison Power

San Jose/Mountain View, California, United States

Ownership: Private
Development stage: Other

Overview

Edison Pharmaceuticals is an active private biotech/pharma firm specializing in small-molecule therapies targeting mitochondrial/redox biology for rare pediatric and adult neurological/metabolic diseases through proprietary platforms and major partnerships with Dainippon Sumitomo Pharma Co., Ltd.

Therapeutic areas: Rare DiseasesMetabolic DisordersNeurology
Modalities: Small moleculeRedox drug
Industry: Biotech

Partnerships

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") – major R&D/commercialization alliance worth up to $4.295 billion for joint development/commercialization of multiple compounds including EPI series drugs.

Beyond the preview

Go deeper on Edison Power.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edison Power.

Explore the full profile